This disease affects an estimated 5 million Americans. Recent medical research has shown that the first initiating event in Alzheimer's disease a condition referred to as a "vascular disorder" within the brain. Zhittya Genesis Medicine's management believes that its drug, when utilized in the early stages of this disease, could via angiogenesis, re-establish vascular order in the brain and treat Alzheimer's Disease. Zhittya's management believes millions of patients suffering with Alzheimer's Disease could potentially benefit from its treatment. The treatment of Alzheimer's disease is clearly an unmet medical need and should qualify for the FDA designation as a "Medical Breakthrough Therapy".